HRP20201867T1 - Imunogeni wt-1 peptidi i postupci za njihovu uporabu - Google Patents

Imunogeni wt-1 peptidi i postupci za njihovu uporabu Download PDF

Info

Publication number
HRP20201867T1
HRP20201867T1 HRP20201867TT HRP20201867T HRP20201867T1 HR P20201867 T1 HRP20201867 T1 HR P20201867T1 HR P20201867T T HRP20201867T T HR P20201867TT HR P20201867 T HRP20201867 T HR P20201867T HR P20201867 T1 HRP20201867 T1 HR P20201867T1
Authority
HR
Croatia
Prior art keywords
cancer
seq
peptide
vaccine
vector
Prior art date
Application number
HRP20201867TT
Other languages
English (en)
Inventor
David A. Scheinberg
Tao DAO
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of HRP20201867T1 publication Critical patent/HRP20201867T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (20)

1. Izolirani peptid koji obuhvaća sekvencu aminokiseline NLMNLGATL (SEK ID BR:6).
2. Izolirani peptid koji obuhvaća sekvencu aminokiseline odabranu od CMTWNLMNLGATLKG (SEK ID BR:14), MTWNLMNLGATLKGV (SEK ID BR:15), TWNLMNLGATLKGVA (SEK ID BR:16), WNLMNLGATLKGVAA (SEK ID BR: 17), i CMTWNLMNLGATLKGVA (SEK ID BR: 22).
3. Izolirani peptid iz patentnog zahtjeva 1 ili 2, pri čemu se izolirani peptid veže na molekulu HLA klase I, molekul HLA klase II, ili njihovu kombinaciju.
4. Izolirani vezujući peptid klase I obuhvaća sekvencu NLMNLGATL (SEK ID BR: 6).
5. Izolirani vezujući peptid klase II koji obuhvaća sekvencu aminokiseline odabranu od CMTWNLMNLGATLKG (SEK ID BR:14), MTWNLMNLGATLKGV (SEK ID BR:15), TWNLMNLGATLKGVA (SEK ID BR:16), i WNLMNLGATLKGVAA (SEK ID BR: 17).
6. Molekula nukleinske kiseline koji kodira peptid iz bilo kojeg od patentnih zahtjeva 1-5.
7. Vektor, kao što je ublaženi virusni vektor ili Salmonella typhi vektor, obuhvaća molekulu nukleinske kiseline iz patentnog zahtjeva 6.
8. Vektor iz patentnog zahtjeva 7, nadalje obuhvaća bilo koji od interleukina 1 do 15, interferon alfa, beta ili gama, faktor nekroze tumora, faktor stimulacije granulocitne-makrofag kolonije (GM-CSF), faktor stimulacije kolonije makrofaga (M-CSF), faktor stimulacije kolonije granulocita (G-CSF), protein aktivirajući neutrofili (NAP), kemoatraktant i faktor aktivacije makrofaga (MCAF), RANTES, makrofagni upalni peptidi MIP-Ia ili MIP-Ib, komplementna komponenta, ili njihove kombinacije.
9. Farmaceutski pripravak koji obuhvaća peptid iz bilo kojeg od patentnih zahtjeva 1-5 ili molekulu nukleinske kiseline iz patentnog zahtjeva 6 ili vektor iz bilo kojeg od patentnih zahtjeva 7-8, i farmaceutski prihvatljiv nosač, pomoćno farmaceutsko sredstvo ili ekscipijens.
10. Cjepivo obuhvaća jedan ili više izoliranih peptida iz patentnih zahtjeva 1-5.
11. Cjepivo iz patentnog zahtjeva 10 još obuhvaća stanicu koja predstavlja antigen i/ili adjuvans, otapalo ili nosač.
12. Cjepivo iz patentnog zahtjeva 10 ili 11 još obuhvaća najmanje jedan dodatni iz WT1 izveden peptid.
13. Cjepivo iz patentnog zahtjeva 12, pri čemu spomenuti adjuvans je QS21, Freund’s nepotpuni adjuvans, aluminij fosfat, aluminij hidroksid, BCG, alauni, faktor rasta, citokin, kemokin, interleukin, Montanide ISA 51, ili GM-CSF.
14. Farmaceutski pripravak iz patentnog zahtjeva 9 ili cjepivo iz bilo kojeg od patentnih zahtjeva 10-13 za uporabu u liječenju subjekta s WT1 eksprimiranim karcinomom ili smanjenje učestalosti WT1 eksprimiranja karcinoma, ili relaps karcinoma.
15. Farmaceutski pripravak ili cjepivo za uporabu sukladno patentnom zahtjevu 14, pri čemu navedeno WT1 eksprimiranje karcinoma je leukemija, dezmoplastični tumor male okrugle stanice, karcinom želuca, karcinom debelog crijeva, karcinom pluća, karcinom dojke, hepatocelularni karcinom, karcinom jajnika, karcinom maternice, karcinom štitnjače, karcinom jetre, karcinom bubrega, Kaposijev sarkom, sarkom, hepatocelularni karcinom, Wilmsov tumor, akutna mijelogena leukemija (AML), mijelodisplastični sindrom (MDS), ili nesitnostanični karcinom pluća (NSCLC).
16. Farmaceutski pripravak ili cjepivo za uporabu sukladno patentnom zahtjevu 15, pri čemu WT1 eksprimiranje karcinoma je mezoteliom.
17. Pripravak koja obuhvaća (a) stanicu koja predstavlja antigen (b) peptid iz bilo kojeg od patentnih zahtjeva 1-5 ili molekulu nukleinske kiseline iz patentnog zahtjeva 6 ili vektor iz bilo kojeg od patentnih zahtjeva 7-8.
18. Upotraba peptida iz bilo kojeg od patentnih zahtjeva 1-5 ili molekula nukleinske kiseline iz patentnog zahtjeva 6 ili vektora iz bilo kojeg od patentnih zahtjeva 7-8 ili cjepiva iz bilo kojeg od patentnih zahtjeva 10-13 ili pripravak iz patentnog zahtjeva 17 za induciranje in vitro stvaranja i proliferacije CTL specifične za stanice WT1 eksprimiranje karcinoma.
19. Uporaba sukladno patentnom zahtjevu 18, pri čemu navedeni karcinom koji eksprimira WT1 je leukemija, dezmoplastični tumor male okrugle stanice, karcinom želuca, karcinom debelog crijeva, karcinom pluća, karcinom dojke, tumor stanice klice, karcinom jajnika, karcinom maternice, karcinom tireoidne žlijezde, karcinom jetre, karcinom bubrega, Kaposijev sarkom, sarkom, hepatocelularni karcinom, Wilmsov tumor, akutna mijelogena leukemija (AML), mijelodisplastični sindrom (MDS), ili nesitnostanični karcinom pluća (NSCLC).
20. Uporaba sukladno patentnom zahtjevu 18 ili 19 pri čemu je karcinom mezoteliom.
HRP20201867TT 2013-01-15 2020-11-25 Imunogeni wt-1 peptidi i postupci za njihovu uporabu HRP20201867T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752799P 2013-01-15 2013-01-15
PCT/US2014/011711 WO2014113490A2 (en) 2013-01-15 2014-01-15 Immunogenic wt-1 peptides and methods of use thereof
EP14741142.5A EP2945647B1 (en) 2013-01-15 2014-01-15 Immunogenic wt-1 peptides and methods of use thereof

Publications (1)

Publication Number Publication Date
HRP20201867T1 true HRP20201867T1 (hr) 2021-02-05

Family

ID=51210182

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201867TT HRP20201867T1 (hr) 2013-01-15 2020-11-25 Imunogeni wt-1 peptidi i postupci za njihovu uporabu

Country Status (17)

Country Link
US (1) US9919037B2 (hr)
EP (2) EP2945647B1 (hr)
JP (4) JP6486278B2 (hr)
CN (4) CN116253788A (hr)
AU (4) AU2014207615B2 (hr)
CA (1) CA2898099A1 (hr)
CY (1) CY1123563T1 (hr)
DK (1) DK2945647T3 (hr)
ES (1) ES2832546T3 (hr)
HR (1) HRP20201867T1 (hr)
HU (1) HUE052541T2 (hr)
LT (1) LT2945647T (hr)
PL (1) PL2945647T3 (hr)
PT (1) PT2945647T (hr)
RS (1) RS61173B1 (hr)
SI (1) SI2945647T1 (hr)
WO (1) WO2014113490A2 (hr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531142T3 (es) 2005-10-17 2015-03-11 Sloan Kettering Inst Cancer Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US9919037B2 (en) 2013-01-15 2018-03-20 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
FR3030573B1 (fr) 2014-12-18 2021-06-11 Veolia Proprete Biostimulation in-situ de l'hydrolyse de la matiere organique pour optimiser sa valorisation energetique
JP6991969B2 (ja) 2015-11-20 2022-03-03 メモリアル スローン ケタリング キャンサー センター 癌を治療するための方法及び組成物
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
EP3440095A1 (en) * 2016-04-06 2019-02-13 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
AU2018234628B2 (en) 2017-03-15 2023-07-20 Cue Biopharma, Inc. Methods for modulating an immune response
EP3600340A4 (en) * 2017-03-31 2021-01-20 ACT Genomics (IP) Co., Ltd. CLASSIFICATION SYSTEM FOR CANCER-SPECIFIC IMMUNOGENIC EPITOPES
WO2018227205A1 (en) * 2017-06-09 2018-12-13 President And Fellows Of Harvard College Compositions for inducing an immune response
WO2019006401A2 (en) * 2017-06-30 2019-01-03 Advaxis, Inc. LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
JP2021534130A (ja) * 2018-08-10 2021-12-09 ユーティレックス カンパニー リミテッド 癌抗原特異的細胞傷害性ｔ細胞
TW202039542A (zh) * 2018-12-19 2020-11-01 美商庫爾生物製藥有限公司 多聚體ｔ細胞調節多肽及其使用方法
CN114072171A (zh) * 2019-04-10 2022-02-18 Slsg有限责任公司 多价免疫治疗组合物和用于治疗wt1阳性癌症的方法
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
EP4085130A4 (en) 2019-12-31 2024-04-10 Elixirgen Therapeutics Inc TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES
EP4087389A4 (en) * 2020-01-09 2024-02-21 Univ Arizona State ANTIBODIES AND METHOD FOR PRODUCING ANTIBODIES
WO2021194940A1 (en) * 2020-03-27 2021-09-30 Children's National Medical Center Sars-cov-2-specific t cells and methods of treatment using them
CN111647066B (zh) * 2020-07-01 2020-12-18 维肽瀛(上海)生物技术有限公司 Wt1多肽肿瘤抑制剂
CN113730562A (zh) * 2021-09-10 2021-12-03 中国人民解放军陆军军医大学 以壳聚糖修饰plga的wt1多肽纳米粒疫苗及其制备方法和应用

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2016100A (en) 1932-01-06 1935-10-01 Schwarzkopf Erich Thermo-magnetically actuated source of power
US2015101A (en) 1933-08-16 1935-09-24 Edna W Dieckmann Terminal fixture aperture indicator
US2016103A (en) 1933-09-01 1935-10-01 Hugo J Chott Dental aligning and testing device
US2016101A (en) 1934-03-26 1935-10-01 Charles A Towne Apparatus for drawing tabs from addressograph plate carriers
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
CA2103577A1 (en) 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2158281A1 (en) 1993-03-15 1994-09-29 Jay A. Berzofsky Peptide coated dendritic cells as immunogens
AU2392795A (en) 1994-04-22 1995-11-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Isolation and characterization of a novel primate t-cell lymphotropic virus and the use of this virus or components thereof in diagnostics assays and vaccines
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6156316A (en) 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
JPH11171896A (ja) 1995-09-19 1999-06-29 Kirin Brewery Co Ltd 新規ペプチド化合物およびその医薬組成物
US5981217A (en) 1995-12-11 1999-11-09 Mayo Foundation For Medical Education And Research DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts
AU1394497A (en) 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6207375B1 (en) 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
ID27813A (id) 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
ATE420112T1 (de) 1998-07-31 2009-01-15 Int Inst Cancer Immunology Inc Krebsantigene, basierend auf dem tumorunterdrückenden genprodukt wt1
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20120301492A1 (en) * 1998-09-30 2012-11-29 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU1675900A (en) 1998-12-22 2000-07-12 Genset Complementary dna's encoding proteins with signal peptides
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
EP1165144A2 (en) 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
US6593299B1 (en) 1999-04-21 2003-07-15 University Of Florida Research Foundation, Inc. Compositions and methods for controlling pests
AU7859900A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
NZ521430A (en) 2000-02-22 2004-04-30 Corixa Corp Compositions comprising 1-4 antigenic peptide fragments of the Wilms' tumour gene product for treatment or prevention of malignant mesothelioma
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1209226A3 (en) 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
EP1371664B1 (en) 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
CA2451846A1 (en) 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003028757A1 (fr) 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
US20050002951A1 (en) 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
KR101050703B1 (ko) 2002-06-12 2011-07-20 추가이 세이야쿠 가부시키가이샤 Ｈｌａ-ａ24-구속성 암 항원 펩티드
JP4839209B2 (ja) 2003-02-06 2011-12-21 アンザ セラピューティクス，インコーポレイテッド 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
US20050008618A1 (en) 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
CA2514288C (en) 2003-03-05 2015-07-07 Dendreon Corporation Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
ATE538809T1 (de) * 2003-06-27 2012-01-15 Int Inst Cancer Immunology Inc Verfahren zur auswahl von geeigneten patienten für den wt1-impfstoff
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
EP1708732B2 (en) 2003-12-01 2016-05-18 Sloan-Kettering Institute For Cancer Research Synthetic hla binding peptide analogues and uses thereof
JP4898452B2 (ja) 2003-12-05 2012-03-14 マルチミューン ジーエムビーエイチ 治療および診断用抗Ｈｓｐ７０抗体
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
US20050260217A1 (en) 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
US20050214268A1 (en) 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
ATE462003T1 (de) 2004-03-31 2010-04-15 Int Inst Cancer Immunology Inc Aus wt1 stammende krebsantigenpeptide
US9629927B2 (en) 2005-07-29 2017-04-25 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses thereof
ES2531142T3 (es) 2005-10-17 2015-03-11 Sloan Kettering Inst Cancer Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
BRPI0619255B8 (pt) 2005-11-30 2021-05-25 Chugai Seiyaku Kabishiki Kaisha composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer
CA2886552A1 (en) 2006-02-22 2007-08-30 Haruo Sugiyama Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
US8288355B2 (en) 2006-03-29 2012-10-16 International Institute Of Cancer Immunology, Inc. siRNA specific to WT1 17AA(−)isoform and use thereof
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
WO2007120603A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic bcr-abl peptides and methods of use thereof
NZ594510A (en) 2006-12-27 2012-06-29 Harvard College Compositions and methods for the treatment of infections and tumors
SI2341142T1 (sl) 2006-12-28 2015-03-31 International Institute Of Cancer Immunology, Inc. HLA-A*1101-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
EP2127671B1 (en) 2007-02-07 2016-09-14 Nec Corporation Therapeutic agent for cancer
CN103103246B (zh) 2007-02-27 2018-05-01 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
CL2008001491A1 (es) 2007-05-24 2008-11-28 Glaxosmithkline Biolog Sa Composicion liofilizada que comprende uno o mas antigenos y un agonista del receptor de tipo toll 9 (tlr9); y procedimiento de preparacion.
KR100995340B1 (ko) 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
MX2010006070A (es) 2007-12-05 2010-12-06 Int Inst Cancer Immunology Inc Composicion de vacuna contra el cancer.
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
EP2283112B1 (en) 2008-05-19 2016-10-12 Aduro Biotech Compositions comprising prfa*mutant listeria and methods of use thereof
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
US20130288236A1 (en) 2009-11-11 2013-10-31 Quest Diagnostics Investments Incorporated Wt1 mutations for prognosis of myeloproliferative disorders
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
CN103298928B (zh) 2010-10-05 2016-04-20 株式会社癌免疫研究所 用于激活辅助性t细胞的方法
SG193337A1 (en) 2011-03-11 2013-10-30 Gilead Calistoga Llc Combination therapies for hematologic malignancies
CN103764826A (zh) 2011-06-28 2014-04-30 株式会社癌免疫研究所 肽癌抗原-特异性t细胞的受体基因
CA2843386A1 (en) 2011-07-29 2013-02-07 Riken Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
US9539299B2 (en) 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
US20140341939A1 (en) 2011-12-14 2014-11-20 National University Corporation Kochi University Modification of helper t cell-inducing polypeptide
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
KR20150092122A (ko) 2012-10-23 2015-08-12 프로비던스 헬스 앤드 서비시즈, 오레곤 질환 치료용 동종 자가포식소체-강화된 조성물
ES2805337T3 (es) 2012-12-17 2021-02-11 Otsuka Pharma Co Ltd Método para activar células T auxiliares
CN104968782B (zh) 2012-12-26 2019-09-06 生物科莫公司 利用人副流感2型病毒载体的疫苗
US9919037B2 (en) 2013-01-15 2018-03-20 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
KR20140100416A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
CN103961305B (zh) 2013-02-05 2019-10-18 日东电工株式会社 经皮给予用wt1肽癌症疫苗带状制剂
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
EP2974734B1 (en) 2013-03-12 2018-10-10 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
EP3607974A1 (en) 2013-03-15 2020-02-12 The Trustees of The University of Pennsylvania Cancer vaccines and methods of treatment using the same
TWI666026B (zh) 2013-03-29 2019-07-21 日商大日本住友製藥股份有限公司 Ｗｔ１抗原胜肽結合疫苗
JP6416877B2 (ja) 2013-04-25 2018-10-31 バクシム アクチェンゲゼルシャフト ウィルムス腫瘍遺伝子ｗｔ１を標的とする癌免疫療法用のサルモネラベースのベクター
US10408840B2 (en) 2013-05-13 2019-09-10 International Institute Of Cancer Immunology, Inc. Method for predicting clinical effect of immunotherapy
JP6406647B2 (ja) 2013-07-02 2018-10-17 公益財団法人がん研究会 細胞性免疫誘導ワクチン
CN105899530B (zh) 2013-11-22 2020-05-08 伊利诺伊州大学理事会 工程化的高亲和力人类t细胞受体
US20160317634A1 (en) 2013-12-18 2016-11-03 Vaximm Gmbh Mafinex-Technologiezentrum Novel msln targeting dna vaccine for cancer immunotherapy
KR102395498B1 (ko) 2014-01-06 2022-05-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
WO2015129790A1 (ja) 2014-02-26 2015-09-03 株式会社バイオイミュランス Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
US10023841B2 (en) 2014-05-23 2018-07-17 Baylor Research Institute Methods and compositions for treating breast cancer with dendritic cell vaccines
EP3231438B1 (en) 2014-12-11 2020-06-17 International Institute of Cancer Immunology, Inc. Wt1 immunotherapy for intraocular angiogenic disease
US10695385B2 (en) 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
US20190054112A1 (en) 2015-09-18 2019-02-21 Moderna Therapeutics, Inc. Polynucleotide formulations for use in the treatment of renal diseases

Also Published As

Publication number Publication date
ES2832546T3 (es) 2021-06-10
AU2020250313B2 (en) 2022-12-15
EP2945647A2 (en) 2015-11-25
LT2945647T (lt) 2021-02-25
JP2016506907A (ja) 2016-03-07
JP2019122377A (ja) 2019-07-25
US9919037B2 (en) 2018-03-20
CN105377291A (zh) 2016-03-02
AU2018241209A1 (en) 2018-11-01
CN105377291B (zh) 2019-04-02
HUE052541T2 (hu) 2021-05-28
US20150352201A1 (en) 2015-12-10
CN110078813B (zh) 2023-03-28
AU2023201564A1 (en) 2023-06-01
PT2945647T (pt) 2020-11-26
JP2021040663A (ja) 2021-03-18
CY1123563T1 (el) 2022-03-24
EP2945647A4 (en) 2016-11-09
CN110078813A (zh) 2019-08-02
JP2022125121A (ja) 2022-08-26
WO2014113490A3 (en) 2015-10-22
AU2018241209B2 (en) 2020-07-09
AU2014207615A1 (en) 2015-07-30
CN116789792A (zh) 2023-09-22
PL2945647T3 (pl) 2021-03-08
DK2945647T3 (da) 2020-11-16
WO2014113490A2 (en) 2014-07-24
AU2020250313A1 (en) 2020-11-12
CA2898099A1 (en) 2014-07-24
RS61173B1 (sr) 2021-01-29
EP3769782A1 (en) 2021-01-27
JP6486278B2 (ja) 2019-03-20
SI2945647T1 (sl) 2021-01-29
CN116253788A (zh) 2023-06-13
EP2945647B1 (en) 2020-09-09
JP6853842B2 (ja) 2021-03-31
JP7097943B2 (ja) 2022-07-08
AU2014207615B2 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
HRP20201867T1 (hr) Imunogeni wt-1 peptidi i postupci za njihovu uporabu
JP2019122377A5 (hr)
JP2021040663A5 (hr)
JP2022125121A5 (hr)
JP2015512866A5 (hr)
ES2848064T3 (es) Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas
JP2009114191A5 (hr)
EP3456339A3 (en) Novel immunotherapy against several tumors, such as lung cancer including nsclc
WO2015169945A3 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
JP2014502156A5 (hr)
JP2012087150A5 (hr)
JP2016128507A5 (hr)
JP2019508403A5 (hr)
HRP20130022T1 (hr) Fuzijski proteini koji sadrže antigene ny-eso-1 i lage-1 za odbacivanje tumora
RU2014109137A (ru) Пептиды mphosph1 и вакцины, включающие их
RU2019114370A (ru) Нуклеотидная последовательность, экспрессирующая якорный белок экзосом для применения в качестве вакцины
RU2013158399A (ru) Пептиды sema5b и содержащие их вакцины
RU2012136464A (ru) Модифицированные пептиды melk и содержащие их вакцины
JP2017522326A5 (hr)
RU2011120447A (ru) Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
JP2019532635A5 (hr)
CN102526724A (zh) 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途
RU2017106887A (ru) Пептид, полученный из koc1, и содержащая его вакцина
Chu et al. A novel adjuvant Ling Zhi-8 for cancer DNA vaccines
RU2013156368A (ru) Средство, индуцирующее иммунитет